Karypharm Reports Positive Results From Phase 2b Clinical Trial of Selinexor
On April 30, Karyopharm Therapeutics, Inc. (KPTI) announced positive results from its phase 2b STORM study examining the effect of Selinexor in patients with penta-refractory multiple myeloma. The clinical trial showed that patients had a 25.4% overall response rate to the treatment. Based on the results, Karyopharm plans to submit a New Drug Application to the FDA during the second half of 2018 with a request for accelerated approval.
Rocket Tickers alerted subscribers to the event at 4:05 pm. The next trade took place for $15.75 at 4:35 pm. Regular market trading opened the next morning at $15.01. After a decline throughout the day after the announcement, the stock price climbed over the next five trading days. Karyopharm closed at $16.94 on May 8.
Visit the Knowledge Center for more information about clinical trials and how to trade them.
Check out our latest Live Webinar which provides more information about price patterns after clinical trial announcements and how to trade them.
Subscribe here if you would like to start receiving these signals in real-time and start trading!